Relapse remains a major cause of mortality among patients receiving allogeneic hematopoietic cell transplantation (HCT). The impact of donor type on post-relapse survival (PRS) has not been widely examined. We compared the survival outcomes for patients relapsing after haploidentical donor transplantation (HIDT) using post-transplant cyclophosphamide with those relapsing after matched-related donor transplantation (MRDT) or matched-unrelated donor transplantation (MUDT) at our institution. Two hundred and thirty-seven consecutive HCT recipients with relapse occurring after HIDT (N = 48), MUDT (N = 87) and MRDT (N = 102) were included in this analysis. Median age was 49 years (19-77 years) and the median time to relapse was 156 days (12-2465) after HCT. HIDT recipients had similar median time to relapse (5.8 vs 4.8 vs 5.5 months, P = 0.638) compared with MUDT and MRDT, respectively. One-year PRS was worse among HIDT recipients compared with MRDT and MUDT (17% vs 46% vs 40%, P o 0.05). In a multivariate analysis, time to relapse ( o3 vs 43 months post transplant), no use of donor lymphocyte infusion (DLI) following relapse, higher Dana Farber disease risk index and HCT comorbidity index scores at the time of transplant and delayed platelet engraftment post transplant were all predictive of worse PRS. This analysis shows that 1-year PRS is inferior among HIDT when compared with MRDT or MUDT. Lower use of DLI after HIDT may have contributed to this inferior survival. 
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is considered to be a curative modality for many patients with high-risk hematologic malignancies. Transplantation using a matchedrelated sibling if available leads to improved outcomes when compared with other graft sources.
1 HLA-haploidentical donor transplantation (HIDT) using a T-cell-replete graft with posttransplant cyclophosphamide has emerged as an alternative graft source for patients lacking a matched-related (MRD) or matchedunrelated (MUD) donor. [2] [3] [4] [5] The use of HIDT with post-transplant cyclophosphamide has been shown to yield low rates of transplant-related mortality, adequate disease control, robust immune reconstitution and overall survival (OS) similar to that seen with optimally MUD transplantations. 2, 6 Relapse remains the main cause of treatment failure after HCT with~30-40% of patients relapse with their original malignancy. 7 Outcomes after relapse after HCT remain poor with a high early mortality and only a small percentage of patients achieving a long-term second remission and prolonged OS. The effect of graft donor source at the time of transplantation on post-relapse survival (PRS) has not been well established. In a recent CIBMTR (Center for International Blood and Marrow Transplantation Research) analysis, patients with relapsed acute myelogeneous leukemia after mismatchedunrelated or double cord transplantation had a worse PRS than recipients of a matched sibling or matched-unrelated HCT. 8 The available treatment options for relapsed patients include intensive chemotherapy, donor lymphocyte infusion (DLI), withdrawal of immunosuppression, second allogeneic HCT and supportive care. [9] [10] [11] Theoretical concerns regarding severe uncontrolled GVHD resulting from the use of unmanipulated DLI in HIDT patients may lead to a reluctance to use DLI following relapse of malignancy in HIDT than following conventional matched donor transplants. However, it has recently been demonstrated that the use of low-dose DLI (10 5 -10 6 CD3+ cells/kg) may be safe following HIDT and can yield durable remissions. 12 The objectives of this study were to compare the use of DLI and rates of PRS after allogeneic transplantation using MRDs, MUDs and HLAhaploidentical donors, and to determine whether the use of DLI is associated with PRS and whether other factors may affect outcomes after relapse of malignancy.
MATERIALS AND METHODS

Study design and patient selection
For this single institution retrospective cohort study, we reviewed our bone marrow transplant database to identify patients with hematologic malignancy who experienced relapse after allogeneic HCT between 1998 and 2014. Two hundred and thirty-seven patients who met the above criteria using an HLA-identical sibling donor (MRD transplantation (MRDT)), 10 of 10 HLA-A, B, C, DRB1 and DQB1 alleles matched volunteer-unrelated donor (MUD transplantation (MUDT)) or T-replete haploidentical graft using post-transplant cyclophosphamide (HIDT) were included in this analysis. The time frame was chosen to allow a minimum of 12 months of post-relapse follow-up for surviving patients. HIDT was performed if there was no suitable MRDT or MUDT donor or such a donor was not available within an acceptable time frame. Transplants that were ex vivo T-celldepleted and cord blood transplants were excluded from the analysis. All patients were transplanted in the outpatient setting with in-patient admissions for complications that cannot be managed as an outpatient. Systematic and prospectively collected information from the bone marrow transplant program database was supplemented by a review of medical records.
Treatment characteristics
The patients underwent conditioning using a variety of preparative regimens and these were classified as myeloablative (MAC), reducedintensity and non-myeloablative according to accepted criteria. 13, 14 All non-myeloablative HIDT (n = 33) were performed using the regimen developed by Johns Hopkins University 4 and consisted of fludarabine 30 mg/m 2 IV once per day on days − 6 to − 2; TBI 2 Gy on day − 1; and cyclophosphamide 14.5 mg/kg IV once per day on days −6 and − 5; and 50 mg/kg once per day on days +3 and +4 using a PBSC or bone marrow graft. Myeloablative HIDT were performed using two different regimens consecutively developed at our institution. 15, 16 Eight patients received a regimen 1: fludarabine 25 mg/m 2 IV once per day on days − 6 to − 2, busulfan 110-130 mg/m 2 IV once per day on days − 7 to − 4 and cyclophosphamide 14.5 mg/kg IV once per day on days − 3 and − 2 and 50 mg/kg once per day on days +3 and +4. Seven patients received regimen 2: fludarabine 30 mg/m 2 once per day on days -7 to − 5, TBI 150 cGy two times daily on days − 4 to − 1 (total dose 1200 cGy) with the same post-transplant therapy as regimen 1. G-CSF-mobilized PBSC (dose capped at 5 × 10 6 CD34+ cells/kg) was used as the graft for all myeloablative HIDT. MUDT and MRDT were performed using standard myeloablative, reduced-intensity and non-myeloablative regimens at our institution. Institutional GVHD prophylaxis for MRD and MUD recipients consisted of a calcineurin inhibitor with methotrexate or mycophenolate mofetil based on conditioning regimen. All HIDT and MUD patients received growth factor support until neutrophil engraftment.
Data collection and study definitions
Demographic and clinical factors examined and included in the analysis were age, gender, year of transplant, diagnosis (acute myelogenous leukemia, myelodysplastic syndrome/myeloproliferative neoplasms/ chronic myelogenous leukemia, acute lymphoblastic leukemia, nonHodgkin lymphoma/Hodgkin lymphoma/chronic lymphocytic leukemia or other malignancy), donor type (MRDT, MUDT, HIDT), graft source (bone marrow or PBSCs), time to relapse, Sorror HCT comorbidity index, 17 CIBMTR risk score and disease risk index. 18 The time to relapse was defined as the interval between day 0 of HCT and the relapse of the primary malignancy. PRS was defined as the time from relapse post transplant to death. Acute and chronic GVHD were prospectively evaluated, graded and documented by a single practitioner within the program.
Statistical analysis
Continuous variables were reported by their median/range and categorical variables by their count/percentage. Patient characteristics and comparison between donor types were compared using the Kruksall-Wallis test for continuous variables and the Pearson's χ 2 test for categorical variables. OS and PRS were estimated by the Kaplan-Meier method. The post-relapse median follow-up time was found by constructing the Kaplan-Meier estimated survival function for the censoring time. Cumulative incidences of NRM, relapse and GVHD were calculated to accommodate competing risks. Outcome comparison between the three donor types was conducted at a fixed time points using the Wald test. Global tests were also conducted to compare outcomes for the three donor types over the entire study period. Global comparisons of PRS were evaluated using the log-rank test. The Gray's test was used to compare cumulative incidences. The P-values associated with HIDT vs MUDT, MRDT vs MUDT and HIDT vs MRDT were corrected by the Bonferroni method. In multivariate analysis, the Cox models were built by testing the following covariates: donor type (MRDT, MUDT or HIDT), patient age, gender, disease risk index (very high, high vs low/intermediate risk), HCT comorbidity index (0, 1-2, ⩾ 3), race, days to ANC 4500, days to platelets 420k, time from HCT to relapse, source (bone marrow vs PBSC), intensity (myeloablative vs reduced-intensity/nonablative), year of transplant and use of DLI. Covariates were selected by the backward elimination method and were held in the Cox models if the P-values were o0.05. Statistical analysis was performed using the SAS software (version 9.3; SAS Institute, Cary, NC, USA).
RESULTS
Patients characteristics
Between 1998 and 2014, 237 patients experienced relapse after allogeneic HCT for hematologic malignancy using MRDT (n = 102), MUDT (n = 87) and HIDT (n = 48). The median follow-up period after relapse was 59 months for the entire population and 63, 64 and 25 months for recipients of MRDT, MUDT and HIDT, respectively. The median time to relapse after HCT was 5.2 months (0.4-81 months), with 62 patients (26%), 77 patients (33%) and 98 patients (41%) relapsing ⩽ 3, 3-6 and ⩾ 6 months post transplant. Median time to neutrophil and platelet engraftment was 15 (0-31 days) and 19 (0-203) days after HCT. Patients receiving HIDT had a prolonged neutrophil and platelet engraftment times (17 and 28 days) compared with MRDT (14 and 18 days) and MUDT recipients (14 and 19 days), P o 0.001 (Table 1) . HIDT recipients were more likely to be transplanted after 2007, receive a bone marrow graft, receive non-ablative conditioning and less likely to receive DLI after relapse. A total of 45 patients received a second transplant after relapse and the donor types for these second transplants were HIDT (n = 6), MRDT (n = 20) and MUDT (n = 19). Recipients of MRDT had a similar incidence of moderatesevere chronic GVHD but a lower incidence of grade II-IV acute GHVD compared with MUDT and HIDT patients (Figure 1 ).
OS and PRS
The OS from time of allogeneic HCT was similar in relapsing patients transplanted from HIDT, MRDT and MUDT ( Figure 1 ). The estimated rates PRS at 1 year were significantly different among patients transplanted from the three different donor types (PRS at 1 year for MRDT, MUDT and HIDT were 46%, 40% and 17%, respectively, with a corresponding P-value of 0.56 for MRDT vs MUDT, o 0.0001 for MRDT vs HIDT and 0.005 for MUDT vs HIDT (Figure 2a) . MRDT recipients had a significantly better median PRS when compared with HIDT patients (8.4 vs 5.9 months, P = 0.04) but the difference between MUDT and HIDT recipients (8.0 vs 5.9 months, P = 0.30) was not statistically significant. DLI effect on PRS A total of 79 patients received DLI infusion for treatment of their relapsed malignancy. Only three HIDT patients (6%) received DLI compared with 48 (47%) MRDT and 28 (32%) MUDT recipients (P o 0.001). Among MRDT and MUDT patients, DLI recipients had a better PRS compared with patients who did not receive DLI after relapse (log-rank P = 0.008). If the comparison was restricted to patients who did not receive DLI, there was no significant difference in PRS between HIDT patients and those receiving transplants from MRDT and MUDT (P = 0.21) (Figure 2b ).
Factors affecting PRS A multivariate Cox model on PRS was conducted using the following variables: age, gender, race, donor type, days to neutrophil engraftment, days to platelet engraftment, time from HCT to relapse, diagnosis, graft source, conditioning intensity, prior autologous transplant, CIBMTR risk, disease risk index, HCT comorbidity index, year of transplant and use of DLI after relapse. Factors significantly associated with PRS are shown in Table 2 . The time to relapse after HCT was significantly correlated with PRS. Patients with a later relapse (43 months) after HCT had a better PRS compared with patients relapsing within 3 months after HCT (hazard ratio = 0.43 for 3-6 months, 95% CI 0.29-0.66, P o 0.001; hazard ratio = 0.29 for 46 months, 95% confidence interval (CI): 0.19-0.43, Po 0.001). Other factors associated with worse PRS were a higher comorbidity index at the time of transplant, very high disease risk index at the time of transplant, no usage of DLI in the after relapse setting and delayed platelet recovery after HCT.
DISCUSSION
Relapse remains the most common cause of treatment failure among patients with hematologic malignancy undergoing allogeneic HCT with incidence ranging from 20 to 50% based on the disease characteristics, conditioning regimen and donor source. 7 Survival after relapse remains dismal with very few patients achieving remission and long-term survival. This study evaluated PRS among patients with hematologic malignancy who experienced disease recurrence after a first allogeneic HCT and investigates the impact of donor type on this outcome. There are several limitations of this study that are inherent to retrospective studies. These include potential unrecognized imbalances between the groups, and biases in the management of individual patients. Some of these limitations are reduced by using a single institution cohort of patients managed with identical supportive care measures with relatively prolonged follow-up. Furthermore, a multivariable analysis was performed to adjust for confounding factors affecting outcome. Donor selection at our center was based on an institutional algorithm that favored an MRD if available, followed by a 10/10 HLA-A, B, C, DRB1 and DQB1 allele MUD as the next best choice. HIDT was performed for patients who lacked such a donor or had an optimally matched Abbreviations: ANC recovery = neutrophil count of 4500/μL for 3 consecutive days; BM = bone marrow; BMT = BM transplantation; CIBMTR = center for international blood and marrow and transplant research; CLL = chronic lymphocytic leukemia; CMI = comorbidity index; CML = chronic myelogenous leukemia; DLI = donor lymphocyte infusion; HD = Hodgkin's disease; HIDT = haploidentical donor transplantation; MDS = myelodysplastic neoplasm; MPS = myeloproliferative neoplasm; MRD = matched-related donor; MUD = matched-unrelated donor; NHL = non-Hodgkin's lymphoma.
MUD donor who could not be accessed sufficiently for the state of the patient's malignancy. The median follow-up was 58 months allowing at least 12 months of post-relapse follow-up for surviving patients. OS after HCT was similar between three different donor types (HIDT, MRDT and MUDT), with a lower incidence of acute GVHD among MRDT and HIDT compared with MUDT recipients. These findings are consistent with previously published reports from our institution and others. 2, 16, 19 One-year PRS was inferior among HIDT patients compared with MUD and MRD (17% vs 40% vs 46%, respectively). PRS was not significantly different between the three donor groups when the analysis was restricted to patients who did not receive DLI after relapse. Only 6% of our HIDT patients received DLI for the treatment of their relapsed disease as compared with 32% and 47% of MUD and MRD recipients, respectively. The exact reasons for the much less frequent use of DLI among HIDT patients were not formally documented but likely relate to concerns about severe GVHD that could theoretically result when unmanipulated DLI are infused into HLA-haploidentical recipients. Our center was among the first to explore the use of T-replete HIDT using HIDT, and for a significant time after we began to use HIDT, there were no published data on the safety of unmanipulated DLI in these patients. In contrast, the use of DLI was already established as the treatment of relapse following MRD and MUD transplants. 20 The limited use of DLI among HIDT may explain the difference seen in PRS among these different donor subtypes. The use of DLI in HIDT patients has been recently reported in several retrospective series.
12,21-23 Low-dose DLI in T-replete HIDT was described by the group at Johns Hopkins. 12 In 40 patients who developed relapse after HIDT and received DLI with a CD3+ cell dose ranging from 1x10 5 to 5x10 7 /kg ideal body weight, acute GVHD developed in 25% of patients and 30% achieved a CR. A similar finding was recently reported by Ghiso et al. 22 where escalated doses of DLI (CD3+ cells 1 × 10 3 to 1 × 10 7 /kg) were administered to patients with relapsed malignancy after HIDT. The incidence of acute GVHD was 10-17%, with a response rate ranging from 33 to 70% depending on disease status at the time of DLI (molecular relapse, hematologic relapse). These studies have suggested that escalating doses of DLI starting at CD3+ cell doses of 10 5 -10 6 /kg may be safe and effective following relapse in HIDT patients. Another potential explanation for the difference in PRS is that the mechanism of relapse might be different among patients receiving different donor sources. Vago et al. 24 evaluated 17 AML patients who relapsed after HIDT and interestingly found that the relapsed leukemic cells lost the haplotype that differed from the donor's haplotype by acquiring a uniparental disomy of chromosome 6p. This escape mechanism rendered the relapsed mutated leukemic cells unrecognizable by the donor and recipient T cells. Treatment of relapsed hematologic malignancy after allogeneic HCT includes withdrawal of immunosuppression, DLI, chemotherapy, radiation or supportive measures for patients not able to tolerate anticancer therapy. Less intensive chemotherapy regimens such as hypomethylating agents and FLT-3 inhibitors have been shown to be an effective and well-tolerated strategy to induce remission among patients with AML relapsing after HCT. 25, 26 Second transplantation using haploidentical donors was recently reported by us and others showing sustained engraftment, low toxicity and 1-year OS ranging from 45 to 50%. 27, 28 Forty-three out of our 48 relapsing HIDT patients (89%) in our analysis received targeted therapy against their relapsed malignancy, and six patients (13%) received a second HIDT transplantation after relapse. The post-relapse treatment for HIDT patients with acute leukemia and MDS was diverse and for 18 AML patients included decitabine (n = 7), azacitidne (n = 4), clofarabine plus low-dose cytarabine (n = 4), fludarabine/high-dose cytarabine (FLAG) (n = 1), mylotarg (n = 1) and no therapy (n = 1). Sorafinib was additionally given to three AML patients with FLT-3-positive AML. As for the seven myelodysplastic syndrome patients, they all received hypomethylating agents. For patients with ALL, T-cell patients received nelarabine (n = 2); Philadelphia-negative B-cell ALL patients received inotuzumab (n = 4); and Philadelphiapositive ALL received ponatinib and nilotinib. Our data and those of other investigators suggest that controlled doses of DLI should more readily be administered to treat relapse following HIDT. The use of immune checkpoint inhibition such as blockade of CTLA4 (cytotoxic T-lymphocyte-associated antigen 4) and the PD-1 (programmed cell death-1)/PD-1 L axis may also be a useful strategy in this setting.
In addition to implementing DLI usage and low-intensity chemotherapy in the treatment of relapse after HIDT, other measure to prevent relapse are of equal importance. These strategies would include improving the preparative regimen, graft engineering, pre-emptive therapy based on minimal residual disease detection, early withdrawal of immunosuppression and maintenance post transplant. 29 We have implemented a few strategies to prevent relapse after HIDT and these include manipulation of the preparative regimen by increasing the conditioning intensity. We currently have a clinical trial with fludarabine-and melphalan-based conditioning to assess if higher intensity (compared with non-ablative fludarabine/cyclophosphamide/TBI) in the HIDT setting can yield lower relapses as has been shown with MRDT and MUDT in the BMTCTN 0901 trial. 16, 30 Other local strategies we are using include post-transplant maintenance therapy such as hypomethylating agents for high-risk MDS and AML patients, 20 clinical trials with FLT-3 inhibitors for AML patients who harbor the FLT-3 ITD mutation and MRD monitoring, especially for patients with Philadelphia-positive ALL. 29 Clinical trials using one or combination of different strategies aiming at preventing relapse and/or using molecular and cellular targets for post-relapse treatment are currently being investigated in many centers with the hope of better disease control after allogeneic HCT. Post-relapse survival after haploidentical HCT M Solh et al
